Gut Microbes The impact of very-low-calorie ketogenic diets on gut microbiota in individuals with obesity: a systematic review and meta-analysis The impact of very-low-calorie ketogenic diets on gut microbiota in individuals with obesity: a systematic re cited 2026 Feb 12];17:2566305
Recent studies have suggested the potential benefits of SGLT2 inhibitors, including empagliflozin, in slowing the progression of chronic kidney disease (CKD) in patients with type 2 diabetes, and reducing the risk of cardiovascular events.The decision to use empagliflozin in CKD should be made on a case-by-case basis, considering the patients overall kidney function and potential risks
Neither option is universally superior, but clear patterns emerge for different patient profiles
Ondansetron IV depending on nausea severity
The future of metabolic management isn't just about less frequent dosing, its about ensuring a comprehensive, high-quality patient experience throughout the entire journey
Patients must strictly follow the doctor's instructions, not self-adjust the dosage, and should not stop the medication without the doctor's approval 5